Nanotechnology is undoubtedly one of the most important technologies in the 21st century, impacting a very broad range of scientific research and industries, from semiconductor ICs, and data storage, nanophotonics, batteries, displays, light emitting diodes, optical communication, virtual reality, biotechnology, medicine, security features, to name just a few. However, the full potential of nanotechnology cannot be utilized, unless we have a nanomanufacturing technology that can manufacture nanostructures with high throughput and low cost.
Of all existing technologies for manufacturing well-defined nanostructures, nanoimprint clearly is one of the most promising ones. Nanoimprint has a unique combination of attributes, including the highest resolution (0.3 nm!), the smallest pitch (<10 nm), large-area (e.g. wall-paper size), high-throughput and low cost, that are unmatchable by other existing methods. As a result, nanoimprint has emerged as one of the most important manufacturing technologies in the 21st century, and is rapidly evolving into a multi-billion-dollar industry. As the inventor of nanoimprint, the author will present his view overview on the status and future of nanoimprint in research and industrialization.
Furthermore, the author will discuss another groundbreaking technology innovation called iMOST™ (instant Mobile Self-Test) – a new platform for healthcare test, that he has invented and developed*. iMOST is designed to offer instant mobile personal self-medical-diagnostic testing that is accurate, reliable, simple to use, affordable to everyone, and can be used anywhere and anytime. iMOST achieved its goals by outside-the-box thinking and a new paradigm, that is fundamentally different from the traditional and that successfully removes several key roadblocks in testing outside a lab.
The new paradigm has the following unique features: (i) “Fault-Tolerant” (ii) “One Device for All” and (iii) low-cost, portable and scalable. The new paradigm is uniquely achieved by using nanotechnology, advance imaging, Nano-Enabled Artificial intelligence/Machine-learning (NEAM) and new bio/chemical processes into diagnostic testing. iMOST is poised to replace traditional, expensive, time-consuming lab test, significantly impacting future telemedicine.
* The iMOST work was performed at Essenlix Corp
Stephen Y. Chou美国工程院院士
Stephen Y. Chou教授在过去40年中的研究涵盖了几个不同的领域：纳米技术、生物工程和医疗诊断测试。他的工作和发明对学术界和工业界都产生了重大影响，并创造了新的研究领域、工业和商业。Stephen Y. Chou教授最著名的发明包括：纳米压印 (纳米级图形化制造新方法，目前已经形成十亿美元级的工业产业) ，7纳米环绕栅极晶体管/存储器，光刻诱导自组装（LISA），单域图形媒体（量子化存储盘），新型纳米光子学器件（如亚波长光学器件，超敏感拉曼和荧光传感器，纳米光子LED和太阳能电池），纳米通道单DNA分子分析仪。他最新的创新是移动式即时自我测试平台（iMOST），人们可以随时随地利用一滴体液和一部智能手机，准确地进行自我疾病诊断和健康测试，测试到结果的时间约为60秒，成本低廉。这些创新是通过纳米技术和纳米辅助人工智能/机器学习（NEAM）实现的。
Stephen Y. Chou教授拥有40多个奖项和荣誉，包括美国国家工程院院士、美国国家发明院院士、IEEE Cledo Brunetti奖、IEEE纳米技术先锋奖、纳米压印先锋奖、纳米50™奖（发明家）、IEEE Fellow、Packard Fellow、光学学会（OSA）Fellow、美国真空学会（AVS）Fellow、 国际纳米制造协会（ISNM）Fellow，入选新泽西州高科技名人堂，中国科学院（CAS）爱因斯坦教授，潘文渊基金会杰出研究奖，麻省理工学院技术评论的 "将改变世界的十大新兴技术 "得主（两次：(i)纳米压印和(ii)纳米通道单DNA分子测序），盖茨基金会大挑战探索竞赛获奖者，美洲中国工程师学会杰出成就奖，美国商务部赞赏奖，《科学美国人》50奖（纳米制造），明尼苏达大学乔治-泰勒杰出研究奖，以及IBM教师发展奖。Stephen Y. Chou教授发表了230多篇期刊论文，490篇会议论文，400多份专利和申请，H-指数为96。